Ratings Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Real-time Estimate Cboe BZX Other stock markets 12:25:59 2024-04-25 pm EDT			5-day change	1st Jan Change
397.7 ^USD	-0.76%		+0.73%	-2.59%

12:26pm	Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $497 From $515	MT
Apr. 23	Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics	DJ

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Over the past four months, analysts' average price target has been revised upwards significantly.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

With a 2024 P/E ratio at 26.9 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
VERTEX PHARMACEUTICALS INCORPORATED	-3.21%	104B	B+
REGENERON PHARMACEUTICALS, INC.	+0.89%	97.42B	B+
ARGENX SE	+0.79%	22.2B	B
BIONTECH SE	-17.97%	21.23B	B+
GENMAB A/S	-11.11%	18.33B	A-
WUXI APPTEC CO., LTD.	-42.83%	16.35B	A-
BEIGENE, LTD.	-16.66%	15.06B	B
NEUROCRINE BIOSCIENCES, INC.	+3.81%	13.98B	C+
SAREPTA THERAPEUTICS, INC.	+31.47%	11.66B	C+
LEGEND BIOTECH CORPORATION	-25.88%	8.22B	D

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes